Tag: biotech

Lila Sciences has announced a significant $115 million extension to its Series A funding round, bringing its total Series A to $350 million and its overall capital raised to $550 million. The round was notably backed by Nvidia's venture arm, NVentures, alongside other key investors, propelling the company's valuation to over $1.3 billion. This funding will accelerate Lila's development of "AI Science Factories," autonomous laboratories designed to revolutionize scientific discovery by integrating advanced AI models with robotic experimentation.

Icon PLC (ICLR) reported its Q2 2025 earnings, revealing a 4.8% year-on-year revenue decrease to $2.017 billion. Despite this, the company demonstrated resilience with improved gross and adjusted EBITDA margins, alongside strategic wins and robust share repurchases. Key financial metrics include a gross margin of 28.3%, adjusted EBITDA of $396 million, and adjusted EPS of $3.26. The company also launched a dedicated center for obesity, signaling a strategic focus on a growing therapeutic area.

Leerink Partners has maintained its Buy rating and set a price target of $240 for ICON PLC (ICLR.US). The firm cited ICON's strong performance in gross bookings, exceeding expectations by over $300 million, which helped to mitigate a higher-than-anticipated cancellation rate. Strengths in the biotech segment and expanded pharmaceutical partnerships were also highlighted as key positive factors.